After years under the radar, Treeline Biosciences disclosed its first clinical candidates targeting various cancers and announced a $200 million extension of its Series A funding, lifting total capital raised beyond $1.1 billion. The programs include a protein degrader against BCL6 in lymphoma, a broad-spectrum KRAS mutation inhibitor applicable to multiple solid tumors, and a third asset licensed from Jiangsu Hengrui Pharmaceuticals focused on T-cell lymphomas. Treeline's approach defies the typical biotech milestone model by backing a diversified pipeline with complementary risk profiles. Investors include notable venture capitalists like Arch Venture Partners, OrbiMed, and GV.